Bruker’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and ongoing portfolio ...

About Medpace Holdings, Inc. and Bruker Corporation Medpace Holdings, Inc. provides clinical research-based drug and medical ... life science mass spectrometry; MALDI Biotyper rapid pathogen ...

In its fourth quarter 2024 investor letter, The London Company SMID Cap Strategy emphasized stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on developing ...

This JupyterNotebook-based code implements a Mass Spectrometry Imaging (MSI) visualiser tool that allows researchers to explore molecular distributions across various samples for MALDI and DESI images ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of additional years of healthy life globally. Some examples of disease areas in which ...

Clinical pharmacology is a branch of biomedical science. It includes drug discovery, the study of the effects of drugs on their targets in living systems and their clinical use, as well as the ...

Good day, and welcome to the Bruker Corporation Fourth Quarter 2024 ... microbiology and infection diagnostics driven by both the MALDI Biotyper and the newly acquired ELITech Molecular ...

Bruker exceeded both EPS and revenue forecasts for Q4 2024. The company reported a 14.6% year-over-year increase in quarterly revenue. Stock price decreased by 0.77% despite the earnings beat. Bruker ...